Gamida Cell - Cord Blood Transplant

Latest News

Learn more about StemEx Clinical Trial

Enhancing the Power of Stem Cell Therapy

Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The company’s pipeline of stem cell therapy products, derived from non-controversial sources such as umbilical cord blood, are in development to treat a wide range of conditions including blood cancers such as leukemia and lymphoma, autoimmune diseases, metabolic diseases and neutropenia.

StemEx® – Gamida Cell’s First Stem Cell Therapy Product

The company’s lead stem cell therapy product, StemEx, is now being studied in an international, Phase III clinical trial as an alternative experimental treatment to a bone marrow transplant for blood cancer patients, who cannot find a matched related bone marrow donor. The StemEx study is enrolling patients at prestigious cord blood transplant centers in Israel, Italy, Hungary, Spain and throughout the U.S. The market launch of the StemEx stem cell therapy product is planned for 2012.

For more information please visit www.stemexstudy.com